Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 27, 2015
Pharmacy Choice - News - Over-the-Counter Drugs - February 27, 2015

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 26     Next >>     Go To Page:

2/27/15 - FDA Approves Allergan's NATRELLE INSPIRA? Round Gel-FilledBreast Implants
Allergan, Inc. today announced that the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA? round gel-filled smooth breast implants. The FDA approval of NATRELLE INSPIRA? round gel-filled implants exemplifies our commitment to scientific innovation and to meeting the dynamic needs of plastic s
2/27/15 - Herantis Pharma financial statements report 2014
Herantis Pharma financial statements report January 1- December 31, 2014 Pharmaceutical development programs advancing as planned- patient results of Phase 2 eye drop study expected by third quarter 2015 Highlights in January- December 2014:* Herantis Pharma Plc was listed on the First North Finland marketplace of NASDAQ OMX Helsinki stock exchange
2/27/15 - HORIZON PHARMA PLC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing at the end of this Annual Report on Form 10- K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report
2/27/15 - The European Automated External Defibrillators (AED) Market is Estimated to Reach $134.2 Million by 2019 - A Report by MicroMarket Monitor
The European automated external defibrillators report defines and segments the concerned market in Europe with an analysis and forecast of the revenue. This market is estimated to grow to about $134.2 million by 2019, at a CAGR of 10.9% from 2014 to 2019.. The major drivers behind the growth of the AED market in Europe are the increasing rate of ca
2/26/15 - IMPAX LABORATORIES INC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
All references to years mean the relevant 12- month period ended December 31. As of February 6, 2015, we marketed 96 generic pharmaceuticals, which represent dosage variations of 29 different pharmaceutical compounds through our own Global Pharmaceuticals division; another five of our generic pharmaceuticals representing dosage variations of two...
2/26/15 - OTC Markets Group Welcomes Newly Verified OTCQB Companies
Release date- 25022015- New York, NY- OTC Markets Group Inc., operator of Open, Transparent and Connected financial marketplaces, today announced the following companies are verified for trading on OTCQB, the venture marketplace for entrepreneurial and development stage companies. GeoVax Labs, Inc.- GeoVax Labs is a clinical-stage biotechnology com
2/25/15 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice...
All comments should be identified with the OMB control number 0910-0139. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. The FDA has the authority und
2/25/15 - COLLABRX, INC. FILES (8-K) Disclosing Other Events
It is currently anticipated that the existing stockholders of Medytox Solutions would hold up to 94.8% of CollabRx's common stock, as well as $25 million of convertible promissory notes issued by CollabRx, following completion of the transaction. If the proposed transaction is completed, the management of Medytox Solutions would become the manageme
2/25/15 - FDA Seeks Comments on Regulatory Status of Ecamsule
WASHINGTON, Feb. 25 The U.S. Department of Health& Human Services published the following proposed rule in the Federal Register from the Food& Drug Administration:. A Proposed Rule by the Food and Drug Administration on 02/25/2015. Sponsors may submit written requests for a meeting with FDA to discuss this proposed order by March 27, 2015.
2/25/15 - FDA Seeks Comments on Regulatory Status of Enzacamene
WASHINGTON, Feb. 25 The U.S. Department of Health& Human Services published the following proposed rule in the Federal Register from the Food& Drug Administration:. A Proposed Rule by the Food and Drug Administration on 02/25/2015. Sponsors may submit written requests for a meeting with FDA to discuss this proposed order by March 27, 2015.
2/25/15 - NEUROMETRIX, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion of our financial condition and results of operations in conjunction with our selected financial data, our financial statements, and the accompanying notes to those financial statements included elsewhere in this Annual Report on Form 10- K. This discussion contains forward-looking statements that involve ris
2/25/15 - Over-the-Counter Sunscreen Drug ProductsRegulatory Status of Enzacamene
FDA -2003- N-0196, FDA -1978- N-0018, and FDA -1996- N-0006 ". The proposed order announces FDA's tentative determination that enzacamene is not generally recognized as safe and effective and is misbranded when used in over-the-counter sunscreen products because the currently available data are insufficient to classify it as GRASE and not misbrande
2/25/15 - QuantRx(R) Biomedical Provides Update on Corporate Developments
QuantRx Biomedical Corporation, an emerging provider of innovative healthcare solutions for feminine care, point-of-care diagnostics, laboratory diagnostics and genomic testing, all of which leverage its robust portfolio of patented intellectual property, is pleased to announce continued progress and exciting development across its business...
2/25/15 - VALEANT PHARMACEUTICALS INTERNATIONAL, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the audited consolidated financial statements, and notes thereto, prepared in accordance with United States generally accepted accounting principles as of December 31, 2014 and 2013 and each of the three years in th
2/24/15 - European Automated External Defibrillators (AED) Market Worth $134.2 Million by 2019
The European automated external defibrillators report defines and segments the concerned market in Europe with an analysis and forecast of the revenue. This market is estimated to grow to about $134.2 million by 2019, at a CAGR of 10.9% from 2014 to 2019.. The major drivers behind the growth of the AED market in Europe are the increasing rate of ca
2/24/15 - Novartis receives FDA approval of Farydak, the first HDAC inhibitor for patients with multiple myeloma
Release date- 23022015- Basel,- Novartis announced today that the US Food and Drug Administration has approved Farydak capsules in combination with bortezomib* and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent. 'Farydak represents a
2/24/15 - VANC Pharmaceuticals Announces Low Cost Alternative Approval of 14 Products From British Columbia Ministry of Health
VANC Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets, is pleased to announce that it has received confirmation from the British Columbia Ministry of Health approving 14 of the Company's generic molecules under the Low Cost Alternative program. The approval of these molecules makes the
2/23/15 - ANI PHARMACEUTICALS INC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
ANI Pharmaceuticals, Inc. and its consolidated subsidiary, ANIP Acquisition Company is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. On June 19, 2013, BioSante Pharmaceuticals, Inc. acquired ANIP Acquisition Company in an all-stock, tax-free reorganization,.
2/23/15 - Endo Pharmaceuticals and BioDelivery Sciences Announce Acceptance of NDA for BELBUCA? (buprenorphine HCl) Buccal Film for the Management of Chronic Pain
DUBLIN and RALEIGH, N.C., Feb. 23, 2015/ PRNewswire/ Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc. announced today that the U.S. Food and Drug Administration has accepted the New Drug Application for the companies' BELBUCA? buccal film under development for the management of pain
2/23/15 - GNW-News: Novartis receives FDA approval of Farydak, the first HDAC inhibitor for patients with multiple myeloma (english)
Novartis receives FDA approval of Farydak , the first HDAC inhibitor for patients with multiple myeloma. Novartis International AG/ Novartis receives FDA approval of Farydak , the first HDAC inhibitor for patients with multiple myeloma. *Farydak is approved under FDA's accelerated approval program; regulatory.
2/23/15 - Novartis receives FDA approval of Farydak, the first HDAC inhibitor for patients with multiple myeloma
Novartis announced today that the US Food and Drug Administration has approved Farydak capsules in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent 1. "Farydak represents an exciting agent with a n
2/23/15 - Peak Pharma Reports Initial Canna-Pet Revenue with 72.7% Gross Margin
Soren Mogelsvang, Peak Pharmaceuticals has proven an ability to provide a short-term path to commercialization in a highly scalable business model. Mogelsvang, and looking further into the upcoming potential of Peak Pharmaceuticals. Peak Pharmaceuticals began developing, manufacturing, and marketing pharmaceutical-grade phytocannabinoid products...
2/23/15 - PFIZER -FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)
Release date- 20022015- Pfizer Inc. announced today that the U.S. Food and Drug Administration has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. 'If approved, RAPAMUNE would be the first F
2/23/15 - Taiho Oncology, Inc. Announces TAS-102 New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd., today announced the New Drug Application for TAS-102, has been accepted for review by the U.S. Food and Drug Administration. "The FDA's filing of the TAS-102 NDA represents a significant milestone for our company and underscores the need for new treatment options for patients
2/23/15 - Use generic name of H1N1 drug, FDA tells pvt doctors [Pune] [Times of India]
Pune: The Food and Drug Administration has told private registered medical practitioners to use the generic name of the drug used to treat swine flu. This will rule out confusion among consumers and make the drug accessible to all, "said S S Mohite, assistant commissioner, FDA, Pune. There has been a surge in H1N1 infection cases across Maharashtra
Articles(s): 1 - 25 of 26     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415